DBV Technologies price target raised to $16 from $7 at H.C. Wainwright

H.C. Wainwright analyst Andrew Fein raised the firm’s price target on DBV Technologies (DBVT) to $16 from $7 and keeps a Buy rating on the shares. The firm views the setup for DBV in the second half of 2025 as “increasingly compelling.” Although Viaskin Peanut remains investigational, the strength and durability of the EPITOPE and EPOPEX data in toddlers, combined with regulatory alignment around the VITESSE trial in older children, continue to reinforce the promise of the company’s epicutaneous immunotherapy platform, the analyst tells investors in a research note.